Last reviewed · How we verify

NCT02310724: T2P2

TODAY2 Phase 2 Follow-up

Completed Last updated 5 August 2021
What this trial tests

trial testing TODAY cohort in Type 2 Diabetes in 517 participants. Completed in 17 January 2020.

Timeline
1 March 2014
Primary endpoint
17 January 2020
17 January 2020

Quick facts

Lead sponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
StatusCompleted
Study typeOBSERVATIONAL
Enrollment517
Start date1 March 2014
Primary completion17 January 2020
Estimated completion17 January 2020
Sites15 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who can join

15 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of T2P2 is to track the progression of T2D and related comorbidities and complications in the TODAY cohort as they transition to young adulthood. We hypothesize that: * Youth-onset type 2 diabetes (T2D) will progress rapidly and result in high rates of diabetes-related medical complications and comorbidities. * The rapid rate of progression is related to increased insulin resistance characteristic of puberty, worse β-cell function, degree of glycemic control, control of non-glycemic factors, and obesity itself.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Long-Term Complications in Youth-Onset Type 2 Diabetes.
    TODAY Study Group, Bjornstad P, Drews KL, Caprio S, et al · · 2021 · cited 367× · PMID 34320286 · DOI 10.1056/nejmoa2100165
  2. Pregnancy Outcomes in Young Women With Youth-Onset Type 2 Diabetes Followed in the TODAY Study.
    TODAY Study Group. · · 2021 · cited 31× · PMID 34880068 · DOI 10.2337/dc21-1071
  3. Development and Progression of Diabetic Retinopathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study.
    TODAY Study Group. · · 2021 · cited 31× · PMID 34531310 · DOI 10.2337/dc21-1072
  4. Diabetes Distress in Young Adults With Youth-Onset Type 2 Diabetes: TODAY2 Study Results.
    Trief PM, Uschner D, Tung M, Marcus MD, et al · · 2022 · cited 27× · PMID 35015056 · DOI 10.2337/dc21-1689
  5. Risk Factors for Diabetic Peripheral Neuropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study.
    TODAY Study Group. · · 2021 · cited 26× · PMID 34716210 · DOI 10.2337/dc21-1074
  6. Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes.
    TODAY Study Group, Shah RD, Braffett BH, Tryggestad JB, et al · · 2022 · cited 16× · PMID 35123868 · DOI 10.1016/j.jdiacomp.2021.108123
  7. Effects of Metabolic Factors, Race-Ethnicity, and Sex on the Development of Nephropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study.
    TODAY Study Group. · · 2021 · cited 16× · PMID 34531309 · DOI 10.2337/dc21-1085
  8. Effect of Early Glycemic Control in Youth-Onset Type 2 Diabetes on Longer-Term Glycemic Control and β-Cell Function: Results From the TODAY Study.
    TODAY Study Group. · · 2023 · cited 6× · PMID 37378967 · DOI 10.2337/dc23-0560

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02310724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing